ArticlePeerJ2025
High-frequency repetitive transcranial magnetic stimulation protects against 6-OHDA-induced Parkinson's disease symptoms by modulating the proNGF-p75NTR-sortilin pathway.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-frequency repetitive transcranial magnetic stimulation (HF rTMS) is a promising non-invasive treatment for Parkinson's disease (PD) in clinical settings. However, the precise mechanisms are incompletely understood. The proNGF-p75NTR-sortilin signaling pathway is closely associated with nigrostriatal dopaminergic (DA) neuron degeneration, a hallmark feature of PD. This study aimed to evaluate the neuroprotective efficacy of HF rTMS on the proNGF-p75NTR-sortilin pathway in PD. Methods: Using a PD rat model induced by 6-hydroxydopamine (6-OHDA), the rats were randomly divided into two groups: sham rTMS group and HF rTMS group. After a 4 w intervention, the rats' motor function was assessed using a rotarod test. Additionally, immunofluorescence technology was used to analyze the DA neurons in the midbrain of PD rats, and immunohistochemistry and Western blot analysis were employed to evaluate the expression levels and effects of proNGF-p75NTR-sortilin in the midbrain following HF rTMS. Results: Our research revealed a significant increase of proNGF expression in reactive astrocytes and upregulated sortilin and p75NTR in DA neurons in the substantia nigra of the hemisphere ipsilateral to the induced lesion, correlated with the degeneration of DA neurons and impaired motor functions. A four-week regimen of HF rTMS, as opposed to sham rTMS, significantly improved the above pathological conditions. The decrease in proNGF-p75NTR-sortilin expression following HF rTMS correlated with a significant increase in DA neuron survival and motor function improvement. HF rTMS exhibited no effects on proBDNF expression. Our study findings indicate that the targeted proNGF-p75NTR-sortilin complex modulation may be an essential mechanism through which HF rTMS exerts its neuroprotective effect. This insight offers a new therapeutic perspective for PD management, highlighting the potential of rTMS to modulate key neurodegenerative pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.